Sonoma Pharmaceuticals prices $4.0M public offering of units at $1.35/unit

Sonoma Pharmaceuticals, Inc.

Offering of 2,962,962 units initially, each unit one share (or pre-funded warrant) and one warrant at $1.35 per unit.
Total gross proceeds ~$4.0M; net proceeds ~$3.5M after underwriting discount and expenses.
Closing occurred April 27-28, 2026 with full over-allotment exercise; 1,650,716 common shares, 1,312,247 pre-funded warrants, 3,407,404 warrants issued.
Warrants exercisable at $1.35 per share for five years; Underwriters' warrants for 5% of sold securities at 110% of offering price.
Net proceeds to be used for general corporate purposes including working capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sonoma Pharmaceuticals, Inc. entered into Underwriting Agreement with Dawson James Securities, Inc. (effective 2026-04-24).

Action: entry
Agreement: underwriting
Counterparty: Dawson James Securities, Inc.
Effective: 2026-04-24

Exact text from the filing

On April 24, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Dawson James Securities, Inc. (the “Underwriter”).

View on SEC.gov

Browse all material agreements →

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-003381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.